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Thymidylate Synthase and Drug Resistance 
G.J. Peters, C.L. van der Wilt, B. van Triest, G. Codacci-Pisanelli, 
P.G. Johnston, C.J. van Groeningen and H.M. Pinedo 
Thymidylate synthase is an important target for both fluorinated pyrimidines and for new folate analogues. 
Resistance to S-fluorouracii (SFU) can be related to insufficient inhibition of thymidylate synthase. The 5FU- 
nucleotide FdUMP induces inhibition of thymidylate synthase which is enhanced and retained for longer in the 
presence of increased folate pools, for which leucovorin is a precursor. In a murine model system, 5FU treatment 
caused a 4-fold induction of thymidylate synthase levels which may have contributed to resistance. Addition of 
leucovorin to this treatment prevented this induction and increased the antitumour effect 2-3-fold. In the clinical 
setting, 5FU administration to patients resulted in approximately 50% inhibition of TS after 48 h. The combination 
with leucovorin resulted in a more pronounced inhibition after 48 h (approximately 70%). A significant relationship 
was observed with outcome of treatment; when thymidylate synthase levels were high and inhibition was low, no 
response was observed. A separate study showed that low thymidylate synthase levels appeared to be an 
independent prognostic factor for adjuvant therapy. 
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INTRODUCTION 
IN THE LAST DECADE, evidence has accumulated suggesting that 
insufficient inhibition of thymidylate synthase may be a major 
resistance mechanism for Sfluorouracil (5FU) [l, 21, both in 
preclinical models and in patients [3-61. In addition, the intrinsic 
cellular thymidylate synthase content may be an important 
prognostic parameter for chemotherapy with 5FU-containing 
regimens [5, 71. Thymidylate synthase plays an essential role in 
the synthesis of DNA; it is the rate-limiting de wm~ enzyme for 
synthesis of thymine nucleotides, one of the precursors for 
DNA synthesis (Figure 1). Thymidylate synthase catalyses the 
methylation of dUMP to dTMP, for which 5,10_methylene- 
tetrahydrofolate (CH,-THF) is the limiting methyl donor. Usu- 
ally the cellular concentrations of both substrates are too low 
[6, 81 to permit the enzyme to operate at its maximal rate. The 
active metabolite of 5FU, 5-fluoro-2’-deoxyuridine-S’-mono- 
phosphate (FdUMP), is a very potent inhibitor of thymidylate 
synthase and competes with dUMP for the same binding site on 
the enzyme. 
This paper describes resistance to 5FU in several model 
systems and in patients, in relation to thymidylate synthase 
content and inhibition, as well as the role of leucovorin in 
improving thymidylate synthase inhibition. Furthermore, the 
application of new immunological and molecular tools in the 
study of thymidylate synthase resistance will be discussed, as 
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Figure 1. Mechanism of inhibition of tbymidylate synthase (TS) by 
FdUMP, including the ternary complex formation. Intracellularly 
both 5FU and leucovorin (LV) have to be metabolised to their 
active form FdUMP and CH,THF, respectively. With tbymidylate 
synthase, they form a ternary complex (represented by the box), 
preventing binding of the natural substrate dUMP to thymidylate 
syntbase, and thus inhibiting its conversion to dTMP and sub- 
sequently DNA synthesis. Thymidine can bypass tbymidylate syn- 
tbase inhibition by its direct conversion to dTMP. 
well as approaches to the use of thymidylate synthase as a 
prognostic parameter. 
SFU RESISTANCE AND THYMIDYLATE SYNTHASE- 
GENERAL ASPECTS 
Inhibition of thymidylate synthase by FdUMP is mediated by 
the formation of a covalent ternary complex between FdUMP, 
thymidylate synthase and CH,-THF (Figure 1). Resistance to 
5FU has been related to insufficient inhibition of thymidylate 
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synthase as well as a number of different mechanisms (Table 1). 
Alterations in the kinetics of thymidylate synthase with respect 
to dUMP and to FdUMP binding [l, 2, 9-121 have been 
reported to be associated with resistance. Treatment with SFU 
usually results in concentrations of FdUMP in cells and tissues 
exceeding IOOO-fold the minimal level required for thymidylate 
synthase inhibition [6, 13-151. However, this inhibition of 
thymidylate synthase can be abrogated by a low ratio between 
FdUMP and the natural substrate dUMP [6]. 
The stability of the ternary complex is highly dependent on 
the availability of CH,-THF [lo, 161 and on the rate of folate 
polyglutamylation. A decreased activity of folyl-polyglutamate 
synthetase has been associated with resistance to 5FU [17]. In 
the absence of CH,-THF, an unstable binary complex is formed 
and, in this case, FdUMP acts as a weak inhibitor of thymidylate 
synthase. Leucovorin is an external source for CH,-THF. After 
administration (either orally or by intravenous (i.v.) infusion) 
leucovorin is readily distributed throughout the body [ 181. After 
transfer across the cellular membrane, leucovorin has to be 
metabolised to CH2THF. Although it has been reported that 
intermediates of this metabolic pathway can also support the 
formation of the ternary complex, CH2-THFis the best substrate 
1191. 
Gene amplification of thymidylate synthase has been observed 
for Sfluoro-2’deoxyuridine (FUdR)-resistant subcell lines [20]. 
Resistance was also observed in a cell line with a variant form of 
thymidylate synthase, encoded by a different gene, which has a 
reduced affinity for FdUMP and CH,-THF [ 121. Evidence for 
gene amplification has also been obtained in one patient with 
colon cancer who developed resistance against 5FU treatment 
Pll. 
SFU-INDUCED INHIBITION OF THYMIDYLATE 
SYNTHASE IN MODEL SYSTEMS 
The potentiating effect of leucovorin on 5FU therapy has been 
shown in in vitro [22] and in z&o models [14, 231 and also in 
patients [18, 221. The thymidylate synthase inhibition that 
Table 1. Mechanisms of resistance to 5FU 
A. Decreased accumulation of activated metabolites 
a. Decreased activation of 5FU 
b. Increased inactivation of 5FU 
c. Increased inactivation of SFU-nucleotides 
B. Target-associated resistance 
a. Decreased RNA effect 
b. Altered effect on thymidylate synthase 
- aberrant enzyme kinetics 
- increased UMP levels 
- decreased FdUMP accumulation 
- decreased stability of ternary complex 
- depletion of intracellular folates 
- decreased polyglutamylation of folates 
- recovery and enhanced enzyme synthesis 
- gene amplification 
- enzyme kinetic variants of the enzyme 
C. Pharmacokinetic resistance 
a. The drug does not reach the tumour 
b. Disease state affects drug distribution 
c. Increased elimination 
Modifiedfrom[18]. 
resulted from 5FU treatment has also been studied in these 
systems [4, 16, 241, but only after a single treatment and after 
a relatively short time interval from 2 to 48 h after drug 
administration. We studied the inhibition of thymidylate syn- 
thase in a murine colon tumour at several time points after 
weekly 5FU, or leucovorin and 5FU therapy or after continuous 
infusion with 5FU. These data were related to the antitumour 
effect of these treatments on Colon 26, which was relatively 
resistant to 5FU. 
Balb/c mice bearing Colon 26 were treated weekly with 
100 mg/kg 5FU alone or with 50 mglkg leucovorin followed 
after 1 h by 50 mg/kg leucovorin and 100 mg/kg 5FU. This has 
been shown to be the most effective regimen to treat this tumour 
with leucovorin and 5FU [23]. Continuous infusions were given 
by implanting subcutaneous pellets, which delivered a dose of 
10 mg 5FUimouselZl days. The antiturnour effect of these 
treatments was evaluated by the growth delay factor (GDF), 
reflecting the gain in tumour doubling times after treatment. 
After 4 weekly treatments, it was observed that leucovorin 
potentiated the antitumour effect of 5FU approximately 2- to 3- 
fold in the Colon 26 tumour (GDF 1.2 versus 2.6) [ 141. GDF of 
continuous infusion 5FU was 2.1 after 3 weeks [25]. 
Tumours from a different group of mice bearing Colon 26 
were removed at several time points (ranging from 3 to 17 days) 
after initiation of treatment and used for enzymatic measure- 
ments. Thymidylate synthase inhibition was evaluated with two 
assays; a ligand-binding assay with [6-3H]-FdUMP to determine 
the free binding sites of the enzyme for FdUMP; and the 3H- 
release assay to determine the catalytic activity (conversion of 
dUMP to dTMP) of thymidylate synthase [14]. Before the 
assays, a part of the tumour homogenate was processed separ- 
ately in order to dissociate the thymidylate synthase ternary 
complexes formed during treatment. This enabled us to measure 
the total catalytic activity (TS-total) and the total number of 
FdUMP binding sites (TS-tot), and to compare these with the 
residual catalytic activity (TS-res) and with the apparently free 
FdUMP binding sites (TS-free) after therapy. 
In non-treated tumours, the FdUMP binding and catalytic 
activity in Colon 26 were 125 pmoVg wet weight and 2324 pmol/ 
mg protein/h [ 141. After one bolus injection, values decreased to 
30% of control, using both assays. The extent and retention 
(at least 3 days) of the thymidylate synthase inhibition was 
comparable for SFU/leucovorin compared with 5FU therapy 
alone. Complete inhibition of thymidylate synthase, as found in 
human tumours [5] and other murine tumours [24], was never 
observed in our murine tumours. After a week, recovery of 
thymidylate synthase was seen, but the TS-total levels in 5FU- 
treated tumours tended to be higher than in the controls 
(Figure 2). After three treatment courses, the change in TS- 
total was more pronounced. Changes in thymidylate synthase 
were more easily detected with the dUMP assay than with the 
FdUMP binding assay. Treatment with 5FU induced a 4-fold 
increase of TS-total catalytic activity in Colon 26, while TS-res 
was 70% of the TS-total activity (day 17). Treatment with 
leucovorin and 5FU resulted in an only 2-fold increase of TS- 
total activity. The extent of thymidylate synthase inhibition after 
three treatment courses of leucovorin and 5FU (day 17) was 
similar to that after the first course (day 3). The high levels of 
TS-res implied that thymidylate synthase inhibition after several 
courses of 5FU treatment was less effective than at the first 
treatment, explaining the 5FU resistance of this tumour. The 
prevention of the increase in thymidylate synthase by leucovorin 
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Figure 2. Inhibition and induction of thymidylate synthase in Colon 
26 tumours treated with 5FU and their prevention by leucovorin (LV). 
Catalytic activity of thymidylate synthase in Colon 26 was measured 
at 10 pM dUMP during three courses of single 5FU or combined 
leucovorin and SFU therapy. Values are means + SD. (n = 3-S). 
Residual thymidylate synthase @I) activity and total thymidylate 
synthase (0) activity were signiftcantly higher in tumours from SFU- 
treated mice, compared with leucovorin/SFU-treated tumours, on 
day 17 (P < 0.001). (From Van der Wilt et al. [14] with permission). 
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Figure 3. Induction of thymidylate synthase levels by treatment of 
cells with a SO% growth-inhibitory concentration of SFU as shown by 
Western blotting using a polyclonal antibody against TS (hindly 
provided by Dr G. W. Aheme, Sutton, U.K. [30]); the 36 hDa band 
shows the native enzyme (n); the higher molecular weight band (t) is 
the ternary complex formed by FdUMP-thymidylate synthase and 
CH,-THF. 
synthase was almost complete, although a large interindividual 
variation was observed (Table 2). In samples from patients 
obtained 1 or 2 days after drug administration, inhibition of 
thymidylate synthase was clearly reduced compared to the 2 h 
samples. After 1 and 2 days, thymidylate synthase activity was 
still 27 and 49%, respectively, of total thymidylate synthase 
levels. This total uninhibited level of thymidylate synthase in 
tumour samples was significantly higher at 23 h than that at 2 
and 45 h. The large variation in the total level of thymidylate 
synthase in these treated tumours was comparable to that found 
in untreated patients [28]. 
In 14 patients, we were able to study both primary tumours 
and liver metastases. No consistent difference in thymidylate 
synthase levels was found between the tumour sites, and in half 
the patients thymidylate synthase activity was higher in the 
primary tumour, while in other patients activity was higher in 
the liver metastases. The concentration of FdUMP, the active 
metabolite of 5FU, showed a time-dependent pattern, with the 
highest levels observed shortly after drug administration and 
decreasing to below detection limits (< 10 pmol/g tissue) in 
most samples after 48 h [ 131. 
In an attempt to enhance the inhibition of thymidylate syn- 
thase, leucovorin (2 h infusion at 500 mg/m* with 5FU injected 
midway infusion) was administered to a subgroup of 11 patients. 
Thymidylate synthase inhibition after 2 days was much more 
pronounced in samples from patients receiving leucovorin-5FU 
administration than after single agent 5FU (Figure 4). In pati- 
ents who received a low dose of leucovorin (25 mg/m*) just 
before the 5FU bolus, thymidylate synthase inhibition was 
reduced compared with the high dose of leucovorin [29]. 
THYMIDYLATE SYNTHASE INHIBITION IN 
RELATION TO RESPONSE 
In 19 patients who were treated with single agent 5FU as a 
hepatic arterial infusion and 8 patients who were treated with 
5FU systemically (with or without leucovorin), we evaluated 
whether the total level and inhibition of thymidylate synthase 
correlated with the outcome of therapy (Figure 5). In samples 
of patients who had received a test dose of 5FU only, a 
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Table 2. Levels of thymidylate synthase in biopsy specimens from tumours after administration of 5F U with 
or without kucovorin 
Time (h) Drugs 
Catalytic activity (pmol/h/mg protein) 
TS-Total TS-Res 
FdUMP binding (fmoYmg protein) 
TS-tot TS-Free 
2 5FU 21 (o-104) 11 (O-39) 58 (33-976) 0 (O-376) 
23 SFU 53* (O-621) 32 (O-372) 120* (O-759) 22 (O-296) 
45 5FU 37 (O-178) 30 (O-152) 64 (o-314) 23 (O-140) 
45 LV-5FU 31 (4-170) 13 (O-19) 92 (O-383) 22 (O-101) 
Biopsy specimens were taken at the indicated time intervals after drug administration. TS catalytic activity was 
measured at 1 JLM dUhW. Values are medians of 13-19 biopsy specimens; the range is indicated in parentheses. 
*Significantly different from values at 2 and 45 h (P < 0.02; two-tailed Mann-Whitney U test). Data are from 
Peters et al. [5]. 
FdUMP binding Catalytic TS 
Figure 4. Inhibition of thymidylate synthase after administration of 
a test dose of SFU or 5FU combined with leucovorin (LV) at 2-45 h. 
Values represent means from lC17 samples (S.E.M. was < 10%). 
The means were calculated from the separate samples as the ratio 
between TS-free/TS-tot x 100% for the FdUMP binding and between 
TS-res/TS-total x 100% for the TS catalytic activity at 10 FM 
dUMP. The leucovorin-5FU data were significantly diierent from 
the 45 h 5FU at the level; 0.001 < P < 0.01 (FdUMP binding); 
(Student’s t-test). Using the Mann-Whitney U test, the 45 h 5FU 
data (both assays) were significantly diierent from the 
leucovorin-5FU data (0.002 < P < 0.02) and from the 2 h 5FU data 
(P < 0.002) (from Peters et al. [S], with permission). 
Range 
Total 
FdUMP 
binding 
sites 
Free 
FdUMP 
binding 
sites 
Tbymidylate synthase activity 
(fmoVmg protein) 
Figure 5. Relation between thymidylate synthase activity as evalu- 
ated with the FdUMP binding assay (TS-tot;TS-free) and response 
(partial response; 9 patients) and no response (stable disease and 
progressive disease; 9 patients) after treatment with single agent 5FU. 
The ranges of thymidylate synthase activities are also shown in the 
right-hand column. The differences in thymidylate synthase levels 
between the patients in the response and no response groups were 
significant at the level P = 0.0123 (TS-tot) and P = 0.0071 (TS-free) 
(modified from Peters et al. [S]). 
high number of total FdUMP binding sites and a high total 
thymidylate synthase catalytic activity were associated with no 
response, whereas a low thymidylate synthase activity was 
associated with a partial response. However, when the patients 
who received leucovorin-5FU as test drugs were included, the 
difference was non-significant (data not shown). Almost no free 
FdUMP binding sites were detected in responding patients who 
had received only SFU as a test drug, while measurable binding 
was observed in non-responding patients (Figure 5). It was 
concluded that a combination of either high FdUMP binding 
(> 100 fmoYmg protein), total catalytic activity (> 90 pmoyh/ 
mg protein), or a poor inhibition with either assay (< 90%), 
were related to no response. In addition to this study, other 
studies have suggested that tumours from patients responding 
to 5FU show greater inhibition of thymidylate synthase than 
tumours of patients with progressive disease [3-51. In breast 
cancer patients, binding of FdUMP and the effect of CH,-THF 
decreased during the development of resistance [4]. These 
results demonstrate that analysis of biochemical parameters in 
tumour biopsies obtained at both short and long time intervals 
after 5FU administration gives valuable information about the 
in vivo mechanism of action of the drug in the tumours of 
patients. 
PROGNOSTIC VALUE OF THYMIDYLATE SYNTHASE 
The above-mentioned studies were performed using tumour 
samples obtained from patients after administration of a test 
dose of 5FU. However, this approach is not always possible in a 
routine setting. Traditionally, thymidylate synthase levels have 
been measured by determining the number of FdUMP binding 
sites or by measurement of the conversion of dUMP to dTMP. 
More recently, new methods have become available, such as 
ELISA assays for thymidylate synthase [30, 311, immunohisto- 
chemistry [7, 32, 331 or semi-quantitative PCR [34, 351. How- 
ever, for each of these methods, it is still not clear whether 
thymidylate synthase is really related to the sensitivity to 5FU. 
In a panel of 19 cell lines from various histological origins (5 
head and neck cancer, 6 breast and 8 from cancer of the digestive 
tract), Beck and associates [36] observed a relatively poor 
relationship between TS activity and sensitivity to 5FU 
(r* = 0.22), whereas, in our hands, a similar relationship 
(r* = 0.27) was observed in a panel of 14 cell lines with a 
different histological origin (colon cancer and head and neck 
cancer) [37]. This means that other factors play a role in the 
sensitivity to 5FU, although thymidylate synthase is probably 
one of the most important. 
Figure 6. Immunohistochemical staining of thymidylate synthase of colon tumours from patients. One cross-section shows a low level of 
thymidylate synthase (A; staining intensity rated at +) and a patient with a high level (B; staining intensity rated as + + +). The polyclonal 
antibody was kindly donated by Dr G.W. Aherne, Sutton, U.K. [30], and was used at a MO-fold dilution. Magnification x 500; the marker in 
the figure represents 20 pm. 
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Figure 7. Correlation of the thymidylate synthase l vel with disease- 
free survival in patients with rectal cancer. The thymidylate synthase 
staining intensity was compared with the percentage ofpatients who 
are disease-free after 5 years. The log-rank test adjusted for Dukes’ 
stage and treatment group were used to test the difference between 
life-table distributions (from Johnston and associates [7], with 
permission). 
Using an ELISA assay for thymidylate synthase, Johnston and 
associates [31] observed a good relationship between FdUMP 
binding activity and ELISA results, as well as between ELISA 
results and sensitivity to SFU. Within several panels of cell lines 
from the same histological origin, we also observed a good 
relationship between thymidylate synthase nzyme activity and 
immunohistochemical staining for thymidylate synthase of cellu- 
lar cytospins [33]. Initial immunohistochemical staining of cross- 
sections of frozen tumour samples demonstrated a intense 
cytosolic staining in tumours with a high thymidylate synthase 
activity, but a faint staining in tumours with a low thymidylate 
synthase activity (Figure 6). The numbers are too small for a 
statistical evaluation of a relationship with the response to 5FU 
therapy. Similarly, we observed a good relationship between 
thymidylate synthase activity and expression of thymidylate 
synthase mRNA as determined using a semi-quantitative RT- 
PCR assay [35]. 
Recent studies have also demonstrated that either thymidylate 
synthase immunohistochemical staining or quantitation of thym- 
idylate synthase mRNA expression can be used to predict the 
outcome of chemotherapy. Johnston and colleagues [7] evaluated 
the thymidylate synthase levels in primary rectal tumours from 
294 patients, enrolled in an adjuvant herapy protocol comparing 
surgery alone with surgery with chemotherapy consisting of 
methyl-CCNU, SFU and vincristine (MOF). Thymidylate syn- 
thase expression apPeared to be a treatment-independent prog- 
nostic factor. The Si-year disease-free survival of patients with 
tumours with a low intensity staining (grading 0 and 1) was 49%, 
while that of patients with a high intensity staining (grading 2 
and 3) was 27% (P < 0.01) (Figure 7). Thymidylate synthase 
expression was also correlated with the benefit of chemotherapy, 
but only in patients with a high-intensity staining. The 5-year 
disease-free survival in the group receiving MOF adjuvant 
chemotherapy was 38% while in patients with surgery alone it 
was 17% (P < 0.01); in the group of patients with a low- 
intensity staining for thymidylate synthase, these values were 36 
and 43%, respectively. Similar differences were observed for 
overall survival. In a prospective study performed in the Nether- 
lands, initial data from 60 patients demonstrate 17 patients have 
a faint staining (rated as +), 29 patients have intermediate 
staining (rated as ++) and 14 patients have intense staining 
(rated as + + +). No data on outcome of therapy are available as 
yet [38]. 
More recent evidence on the prospective value of thymidylate 
synthase has been obtained in patients with gastric cancer who 
received SFU therapy [39, 401. Thymidylate synthase mRNA 
expression was quantitated using a RT-PCR assay. All patients 
above a certain threshold expression level progressed on chemo- 
therapy, while patients who responded had a significantly lower 
thymidylate synthase xpression level. 
CONCLUSION 
Both insufficient thymidylate synthase inhibition and high 
intrinsic levels of thymidylate synthase are related to several 
forms of resistance to therapy with SFU or with leucovorin and 
5FU. High thymidylate synthase levels may also be associated 
with poor prognosis of chemotherapy. This information can be 
used to design more effective chemotherapy regimens, such as 
the use of more specific folate-based thymidylate synthase 
inhibitors [41]. 
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